Meeting Minutes, Open Session, Drug Utilization Review Board July 21, 2021		
Drug Utilization Review Board *Due to COVID-19, this meeting was held virtually.	**DUR Board Members:** Moneeshindra Mittal, MD, Chair (Present) James Backes, PharmD, Interim Chair (Present) Jennifer Clair, MD (Present) Gregory Burger, PharmD, CPPS, FASHP, EMT (Present) Michele Reisinger, DNP, APRN, FNP-BC (Present) Kristen Powell, PharmD (Present) Arthur Snow, MD (Present) **KDHE/DHCF/Contractor Staff:** Annette Grant, RPh. (Present) Victor Nguyen, PharmD (Present) Carol Arace, Administrative Specialist (Present) **DXC Technology Staff/KEPRO Staff** Kathy Kaesewurm, RN, BSN (Present) Harry Vu, PharmD (Present) Christina Faulkner, PharmD, BCPS (Present) **MCO Staff:** Sunny Bounyalath, PharmD, UnitedHealthcare Community Plan (Present) Mark DeMary, PharmD, Aetna Better Health of Kansas (Present) Angie Yoo, PharmD, Sunflower State Health Plan (Present)	**Public Attendees**: Akesha Coleman, Amara Udokporo, Dave Miley, David Alfred, David Cram, David Large, Donna Osterland, Erin Hohman, Gina Heinen, Jessica Chardoulias, Jim Baumann, John Bullard, Keith Gulley, Ken Wood, Kim Walter, Kurt Hendrickson, Laura Hill, Marc Parker, Mary Shefchyk, , Nishil Patel, Phil King, Robert Firnberg, Ricky Roberson, Selina Gierer, Stacey Repotski, Tara McKinley (Only individuals that provided their full name are listed)

TOPIC	DISCUSSION	DECISION
I. Call to Order	Dr. Mittal called the meeting to order at 10:07 AM.	
Announcements and Introductions	The meeting operator informed everyone of her role and the process for the meeting. The State welcomed new members Gregory Burger, PharmD, CPPS, FASHP, EMT and Michele Reisinger, DNP, APRN, FNP-BC to the DUR Board. New members Dr. Burger and Dr. Reisinger provided brief introductions of their respective professional backgrounds. Ms. Grant introduced Sunny Bounyalath, PharmD from UnitedHealthcare Community Plan.	
II. Old Business **A. Review and Approval of April 21, 2021 Meeting Minutes**	**Board Discussion:** Dr. Mittal asked if there were any amendments/changes to the minutes requested.	Dr. Snow motioned to approve. Dr. Powell seconded the motion. The motion was approved unanimously.
III. New Business **A. Mental Health Medication Advisory Committee (MHMAC)** **1. ADHD Medications**	**Background:** The State oriented new board members to the process for mental health drug PAs. At the May 2021 MHMAC meeting, the committee revised the ADHD Medications – Safe Use for All Ages criteria to include Evekeo® ODT, Qelbree®, and Azstarys™ and updates to the dosing limits table. Step therapy for Qelbree® was also reviewed. **Public Comment:** None. **Board Discussion:** Dr. Powell asked whether specific time limit existed for previous trial to have occurred. The State affirmed that as long as previous trial is documented in patient record, no time limitation enforced.	Dr. Backes motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.
2. Antidepressant Medications	**Background:** At the May 2021 MHMAC meeting, the committee revised the Antidepressant Medications – Safe Use for All Ages criteria to reflect Spravato® labeling updates. **Public Comment:** None.	Dr. Powell motioned to approve. Dr. Burger seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
	Board Discussion: None.	
3. Antipsychotic Medications	**Background:** At the May 2021 MHMAC meeting, the committee revised the Antipsychotic Medications – Safe Use for All Ages criteria to include step therapy requirements for Secuado®. **Public Comment:** None. **Board Discussion:** None.	Dr. Snow motioned for approval as amended. Dr. Clair seconded the motion. The motion was approved unanimously.
B. Revised Prior Authorization (PA) Criteria **1. Crohn's Disease Agents**	**Background:** This revision updates requirements for renewal prior authorization requests. It also updates requirements for Tysabri®. **Public Comment:** Laura Hill, Abbvie, pointed out a new recommendation from the recently updated American Gastroenterological Association guidelines. Laura suggested allowing patients earlier access to biologics and to move renewal requirements to provider attestation of benefit. David Cram, Takeda, generally agreed with statements made by Laura and made statements regarding the early and late stages of the disease. **Board Discussion:** The Board had discussion over which IBD guidelines to use. The topic was placed on hold for discussion towards the end of the meeting. Upon return, the State mentioned the discussion points from the Ulcerative Colitis PA and asked the Board to consider the criteria as originally proposed. That the State would review the criteria again at the next meeting. (Please see the Ulcerative Colitis PA section for additional information that pertains to this PA discussion.)	Dr. Mittal tabled the discussion until towards the end of the meeting. Upon return, Dr. Backes motioned to approve the criteria as originally proposed. Dr. Burger seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
2. Oncology Agents	**Background:** This revision includes the addition of several drugs to the list of agents requiring prior authorization **Public Comment:** None. **Board Discussion:** Dr. Mittal asked for clarification on development of PA criteria. The State said that the Board is approving criteria to be based upon package insert for each drug for Fee-For-Service purposes. The Managed Care Organizations (MCOs) will manage these drugs via a State policy allowing an oncology vendor to manage these drugs. Dr. Backes suggested the development of an oncology subcommittee.	Dr. Snow motioned to approve. Dr. Burger seconded the motion. The motion was approved unanimously.
3. Oncology – Auxiliary Treatment Agents	**Background:** This revision includes the addition of several drugs and consolidation of existing criteria (Anti-emetics: Neurokinin 1 (NK-1) Antagonists/NK-1 Antagonist Combinations). **Public Comment:** None. **Board Discussion:** None.	Dr. Clair motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.
4. Migraine Prophylaxis Agents	**Background:** This revision includes the addition of Nurtec® ODT and adds step therapy. **Public Comment:** Nishil Patel, Amgen, yielded their time back to the Board. **Board Discussion:** None.	Dr. Snow motioned to approve. Dr. Powell seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
5. Weight Loss Agents	**Background:** This revision includes addition of Wegovy™ and revises the initial and renewal criteria for all agents. **Public Comment:** Jessica Chardoulias, Novo Nordisk, gave clinical information regarding Saxenda and Wegovy. Jessica pointed out that the Saxenda package insert has stop criteria if the adolescent patient has not lost at least 1% BMI, compared to the proposed 4% BMI reduction. **Board Discussion:** The Board discussed the clinical significance of 1% BMI reduction in adolescents versus the proposed 4% reduction. The State mentioned that coverage of this drug class is optional and that these agents are expensive. That a small reduction is not clinically beneficial. The Board voted on the originally proposed criteria.	Dr. Clair motioned to approve. Dr. Powell seconded the motion. The motion was approved unanimously.
6. Ulcerative Colitis (UC) Agents	**Background:** This revision includes addition of Zeposia® to the list of agents requiring prior authorization and includes dosing information and renewal criteria. **Public Comment:** Laura Hill, Abbvie, expressed concern about the renewal criteria. David Cram, Takeda, discussed recent studies comparing Entyvio® to Humira®. **Board Discussion:** The State mentioned that this part of the PA draft was similar to the Crohn's PA and that PA was reviewed by some pediatric providers prior to bringing the PA to the DUR Board. The State had made some changes based upon that review and this part of the PA was not brought up as a concern for those providers. The State requested that both PAs be approved based upon that and that the State has a solid process from which PAs are created. That clinical guidelines are used versus package insert now because the package insert gives only the clinical trial information, but clinical guidelines also take into consideration post marketing patient and provider experience.	Dr. Backes motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
	Collectively, many specialists are reviewing all the clinical information and coming up with best practices, etc.	
7. Minimum Requirements Prior Authorization	**Background:** This revision reflects an update to the age indication for Trikafta® use. **Public Comment:** None. **Board Discussion:** None.	Dr. Powell motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.
8. Opioid Products Indicated for Pain Management	**Background:** This revision includes the addition of Qdolo™ and finalization of a minor clarification regarding approval duration. **Public Comment:** None. **Board Discussion:** None.	Dr. Burger motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.
9. Atopic Dermatitis Agents	**Background:** This revision includes updates to the initial and renewal criteria. **Public Comment:** Jim Baumann, Pfizer, yielded their time back to the Board. **Board Discussion:** None.	Dr. Backes motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.
IV. Appointment of Chairperson and Interim Chairperson	**Background:** Annual nominations/vote for Chairperson, Interim Chairperson positions. **Public Comment:** None.	Dr. Snow motioned to approve. Dr. Powell seconded the motion. The motion was approved unanimously

TOPIC	DISCUSSION	DECISION
	Board Discussion: Vote to retain current seats, Dr. Mittal abstained from vote, accepted Chairperson; Dr Backes also abstained from vote, accepted Interim Chairperson.	
V. Adjourn	The meeting adjourned at 11:57am	Dr. Burger motioned to adjourn. Dr. Clair seconded the motion. Motion to adjourn carried unanimously

The next DUR Board meeting is scheduled for October 20, 2021.

All approved PA criteria are posted to the KDHE website- http://www.kdheks.gov/hcf/pharmacy/pa criteria.htm